← Back to headlines
RBC Capital Initiates Bristol Myers Coverage with $60 Target
RBC Capital initiates coverage on Bristol Myers (BMY) with a $60 target, noting the depth of its late-stage pipeline.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
